Bibliography
Found 39 results
Filters: Keyword is Antiretroviral Therapy, Highly Active [Clear All Filters]
Older age and plasma viral load in HIV-1 infection. AIDS. 2004 ;18 Suppl 1:S87-98.
Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol. 2008 ;64(5):566-72.
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 ;65(1):65-70.
Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS. 2009 ;23(17):2317-22.
. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010 ;75(23):2087-96.
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology. 2012 ;78(7):485-92.
Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother. 2012 ;56(4):1985-9.
Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.
HIV gp120 induces mucus formation in human bronchial epithelial cells through CXCR4/α7-nicotinic acetylcholine receptors. PLoS One. 2013 ;8(10):e77160.
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology. 2013 ;81(17):1492-9.
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 ;82(23):2055-62.
Brain morphometric correlates of metabolic variables in HIV: the CHARTER study. J Neurovirol. 2014 ;20(6):603-11.
The impact of neurobehavioral features on medication adherence in HIV: evidence from longitudinal models. AIDS Care. 2014 ;26(1):79-86.
. Factors related to HIV-associated neurocognitive impairment differ with age. J Neurovirol. 2015 ;21(1):56-65.
. Insulin-like growth factors and related proteins in plasma and cerebrospinal fluids of HIV-positive individuals. J Neuroinflammation. 2015 ;12:72.
. Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2015 ;69(1):29-35.
Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. J Infect Dis. 2016 ;213(7):1065-73.
Brain and liver pathology, amyloid deposition, and interferon responses among older HIV-positive patients in the late HAART era. BMC Infect Dis. 2017 ;17(1):151.
. Frontline Science: CXCR7 mediates CD14CD16 monocyte transmigration across the blood brain barrier: a potential therapeutic target for NeuroAIDS. J Leukoc Biol. 2017 ;102(5):1173-1185.
. Modeling brain lentiviral infections during antiretroviral therapy in AIDS. J Neurovirol. 2017 ;23(4):577-586.
. Personalized Risk Index for Neurocognitive Decline Among People With Well-Controlled HIV Infection. J Acquir Immune Defic Syndr. 2017 ;76(1):48-54.
.